Shares of DaVita HealthCare Partners Inc. (NYSE:DVA) have been given an average rating of “Hold” by the thirteen research firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $69.88.

DVA has been the topic of several recent research reports. J P Morgan Chase & Co increased their target price on DaVita HealthCare Partners from $4.90 to $84.00 and gave the stock a “strong-buy” rating in a research report on Thursday. Robert W. Baird restated a “hold” rating and set a $63.00 target price on shares of DaVita HealthCare Partners in a research report on Friday, November 10th. SunTrust Banks increased their target price on DaVita HealthCare Partners to $70.00 and gave the stock a “hold” rating in a research report on Thursday. Zacks Investment Research downgraded DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, Raymond James Financial upgraded DaVita HealthCare Partners from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $65.00 to $84.00 in a research report on Thursday.

Hedge funds have recently modified their holdings of the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DaVita HealthCare Partners in the third quarter worth $154,000. Pzena Investment Management LLC raised its position in shares of DaVita HealthCare Partners by 2.1% in the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock worth $220,000 after buying an additional 71 shares in the last quarter. Eqis Capital Management Inc. raised its position in shares of DaVita HealthCare Partners by 62.5% in the third quarter. Eqis Capital Management Inc. now owns 7,473 shares of the company’s stock worth $444,000 after buying an additional 2,873 shares in the last quarter. Jensen Investment Management Inc. raised its position in shares of DaVita HealthCare Partners by 24.2% in the second quarter. Jensen Investment Management Inc. now owns 9,740 shares of the company’s stock worth $631,000 after buying an additional 1,900 shares in the last quarter. Finally, Accident Compensation Corp raised its position in shares of DaVita HealthCare Partners by 147.5% in the second quarter. Accident Compensation Corp now owns 15,100 shares of the company’s stock worth $978,000 after buying an additional 9,000 shares in the last quarter. Institutional investors own 85.32% of the company’s stock.

Shares of DaVita HealthCare Partners (NYSE DVA) opened at $67.14 on Friday. The stock has a market capitalization of $12,350.00, a price-to-earnings ratio of 17.41, a price-to-earnings-growth ratio of 12.28 and a beta of 0.97. DaVita HealthCare Partners has a 12-month low of $52.51 and a 12-month high of $70.16. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79.

DaVita HealthCare Partners (NYSE:DVA) last posted its earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.13). The company had revenue of $3.92 billion for the quarter, compared to analysts’ expectations of $3.91 billion. DaVita HealthCare Partners had a return on equity of 13.31% and a net margin of 3.40%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.95 EPS. sell-side analysts forecast that DaVita HealthCare Partners will post 3.42 EPS for the current year.

DaVita HealthCare Partners announced that its Board of Directors has initiated a share buyback program on Tuesday, October 10th that allows the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: “DaVita HealthCare Partners Inc. (DVA) Receives Consensus Recommendation of “Hold” from Analysts” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/08/davita-healthcare-partners-inc-dva-receives-consensus-recommendation-of-hold-from-analysts.html.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.